Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study.
OBJECTIVE
To investigate the role of body mass index (BMI) and weight in the long-term efficacy of etanercept in patients with psoriasis.


METHODS
Medical records were retrospectively analysed. Extracted data included weight, BMI, comorbidities and psoriasis area severity index (PASI). Patients were stratified by weight (<80 kg or ≥80 kg) and BMI (healthy, BMI 22 - 24.99 kg/m2; overweight, BMI 25 - 29.99 kg/m2; obese, BMI ≥30 kg/m2).


RESULTS
The study included 66 patients. Body weight had no effect on etanercept efficacy. There was a significant reduction in etanercept efficacy in obese patients (n = 12) compared with healthy weight (n = 33) or overweight (n = 21) patients.


CONCLUSIONS
Obesity has a negative effect on the efficacy of etanercept in psoriasis.
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy alessandro.giunta@uniroma2.it.
Alessandro
A
Giunta
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Graziella
G
Babino
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Manuela
M
Ruzzetti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Sara
S
Manetta
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Sergio
S
Chimenti
Department of Dermatology, University of Rome Tor Vergata, Rome, Italy.
Maria
M
Esposito
Anti-tumor necrosis factor-α; body mass index; body weight; etanercept; obesity; psoriasis
Int J Immunopathol Pharmacol. 2009 Jan-Mar;22(1):219-25
19309569
Rheumatology (Oxford). 2014 May;53(5):875-81
24407233
Br J Dermatol. 2006 Oct;155(4):808-14
16965432
Pharmacol Res. 2008 Apr;57(4):290-5
18400510
Drug Dev Res. 2014 Nov;75 Suppl 1:S27-30
25381970
J Eur Acad Dermatol Venereol. 2008 Mar;22(3):341-4
18005022
J Dermatolog Treat. 2012 Dec;23(6):404-9
21781016
J Am Acad Dermatol. 2008 Mar;58(3):443-6
18083274